The position statements of the American Academy of Clinical Toxicology (AACT) suggests the following when applied to large VPA overdose (ref 12 to 14) SDAC Should not be administered as a routine intervention It can be considered up to an hour post ingestion (4 hours in slow or enteric release preparations) in those who have ingested potentially toxic dose, and who have an intact, protected airway Usual dose is 1gm/kg MDAC Reported to be used in multiple cases of VPA overdose, but AACT position statement states that there is no evidence that MDAC increases the elimination of VPA, and should only be considered in specific overdoses (carbemazepine, dapsone, phenobarbitone, quinine, or theophylline) it may aid decontamination (rather than enhanced elimination) given the slow absorption of valproate WBI consider in sustained release or enteric-coated ingestions that are potentially toxic or life threatening in patients presenting greater than two hours
It is frequently included in sports nutrition products and is often used by athletes who follow structured training routines
Injecting into areas with scars, bruises, moles, or rashes increases the chances of severe reactions and may even affect how well the medication is absorbed
Must only be handled by qualified professionals conducting authorised scientific research
Scientists consider that once triggered, growth hormones may be naturally secreted, maintaining levels of growth hormones in the organism
Cardiovascular concerns, including an increased risk of heart disease, irregular heart rhythms, and reduced cardiac performance
